Ionis Pharma (IONS) Stock Forecast & Price Target

Ionis Pharmaceuticals is supported by a differentiated antisense platform that has already produced multiple marketed therapies across neurology, cardiovascular, metabolic, rare disease, and amyloidosis indications, including Spinraza in 2016, Qalsody in 2023, Tegsedi in 2018, Waylivra in Europe in 2019, Wainua in 2024, and its first two independent launches in 2025 for Tryngolza and Dawnzera. The company’s broad and deep pipeline, combined with recent approval-driven revenue visibility such as Zanvastro’s approval in Alexander disease and an estimated peak annual revenue of about $160M, supports confidence in its ability to continue converting its scientific platform into commercial products even as individual programs like pelacarsen are reset following setbacks. Financially, the use of a DCF through 2036 with an 8.8% WACC, a 0% terminal growth rate, and a 15% tax rate beginning in 2028 reflects a disciplined valuation framework, while the monetization of the PRV from Zanvastro and the company’s established launch history reinforce the view that Ionis has meaningful long-term value creation potential.

Ionis Pharmaceuticals is challenged by a business model that still depends heavily on a relatively small number of commercial assets and uncertain royalty streams, with even favorable sefaxersen economics described as tiered high-teens-to-20% royalties and no disclosed timing or amounts for key future milestones. Although the FUSION study for ulefnersen showed statistical significance on a Day 505 composite endpoint in a 73-patient Phase 3 trial, the lack of a standalone survival benefit, limited FUS-ALS prevalence of about 0.6% of ALS patients, and undisclosed subgroup analyses suggest the program’s commercial impact may remain modest. The company’s newer launches, including Tryngolza and Dawnzera in 2025, add promise, but competitive pressure in sHTG, questions around broader adoption outside high-need patients, and dependence on regulatory execution across the pipeline make the long-term fundamental outlook fragile.